NCT04283006View on ClinicalTrials.gov

A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 23, 2018

Primary Completion Date

May 23, 2023

Study Completion Date

May 23, 2028

Conditions
Relapsed and RefractoryLymphoid Hematological Malignancies
Interventions
DRUG

CD20/CD22 dual Targeted CAR T-cells

Each subject receive CD20/CD22 dual Targeted CAR T-cells by intravenous infusion

Trial Locations (1)

310003

RECRUITING

The First Hospital of Zhejiang Medical Colleage Zhejiang University, Hangzhou

All Listed Sponsors
collaborator

Yake Biotechnology Ltd.

INDUSTRY

lead

He Huang

OTHER